Beroni Group Advances Coronavirus Research

Beroni Group, a biopharmaceutical developer focused on treating of global diseases, will leverage its nanobody technology for the novel coronavirus (COVID-19) in collaboration with Tianjin University in China to advance into cytological experiments in March 2020.

The research team has been able to obtain information on the coronavirus nanobody sequence and the complex crystal structure of SARS-CoV-2, the virus causing the infection. After evaluating the effect of the antibody modification, the teams are now moving into cytological experiments, which are expected to be completed this month.  Shortly thereafter, animal experiments will be conducted followed by clinical trials, which are expected to occur in April 2020.

Concurrently, Beroni is in discussions with an international CRO/CDMO company with operations in the USA, Europe and China to use their research and manufacturing facilities to accelerate the clinical trials for both the diagnostic kit and medical treatment.  
 
Jacky Zhang, Chairman and CEO of Beroni Group, said, "As the novel coronavirus is now spreading globally, we are leveraging our talents and international government relationships to expedite the clinical study protocol so we can quickly produce a medical solution to help stop the spread of this infectious disease. We are confident of finding a long-term solution for the coronavirus using nanobody technology."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.